company background image
WGS logo

GeneDx Holdings NasdaqGS:WGS Voorraadrapport

Laatste prijs

US$75.18

Marktkapitalisatie

US$2.1b

7D

-8.0%

1Y

5,014.3%

Bijgewerkt

07 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

GeneDx Holdings Corp.

NasdaqGS:WGS Voorraadrapport

Marktkapitalisatie: US$2.1b

WGS Overzicht aandelen

GeneDx Holdings Corp. levert via haar dochterondernemingen diagnostische en informatiediensten met betrekking tot genomica.

GeneDx Holdings Corp. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor GeneDx Holdings
Historische aandelenkoersen
Huidige aandelenkoersUS$75.18
52 Week HoogtepuntUS$89.11
52 Week LaagUS$1.16
Bèta2.38
11 maand verandering38.38%
3 maanden verandering129.63%
1 Jaar Verandering5,014.29%
33 jaar verandering-71.20%
5 jaar veranderingn/a
Verandering sinds IPO-76.75%

Recent nieuws en updates

US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

Nov 01
US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term

Oct 30

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

Oct 21

Recent updates

US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

Nov 01
US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term

Oct 30

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

Oct 21

After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Oct 04
After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

Aug 29
Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform

Aug 19

Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

Jul 27
Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

Jun 12
GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

Jun 06

Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

Apr 24
Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Feb 23
GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Feb 22
The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Dec 20
Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Nov 02
Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Nov 01
Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Sema4 names Kevin Feeley as CFO

Aug 26

Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Aug 20
Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 19
Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Sema4 Q2 2022 Earnings Preview

Aug 12

Sema4 Holdings, Big Data For Precision Medicine Solutions

Jul 18

Rendement voor aandeelhouders

WGSUS HealthcareUS Markt
7D-8.0%4.2%2.3%
1Y5,014.3%6.9%35.1%

Rendement versus industrie: WGS overtrof de US Healthcare industrie, die het afgelopen jaar een rendement 6.9 % opleverde.

Rendement versus markt: WGS overtrof de US markt, die het afgelopen jaar een rendement opleverde van 35.1 %.

Prijsvolatiliteit

Is WGS's price volatile compared to industry and market?
WGS volatility
WGS Average Weekly Movement16.8%
Healthcare Industry Average Movement6.9%
Market Average Movement6.2%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: De aandelenkoers van WGS is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 17% ) van WGS is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
20171,000Katherine Stuelandwww.genedx.com

GeneDx Holdings Corp. biedt via haar dochterondernemingen genomica-gerelateerde diagnostische en informatiediensten aan. Het bedrijf biedt Centrellis, een AI-gedreven gezondheidsplatform dat digitale tools en kunstmatige intelligentie integreert waarmee wetenschappers klinische en genomische gegevens kunnen opnemen en synthetiseren om uitgebreide gezondheidsinzichten te leveren. Het biedt genetische diagnostische tests, screeningsoplossingen en informatie met een focus op kindergeneeskunde, zeldzame ziekten voor kinderen en volwassenen en erfelijke kankerscreening.

GeneDx Holdings Corp. Samenvatting

Hoe verhouden de winst en inkomsten van GeneDx Holdings zich tot de beurswaarde?
WGS fundamentele statistieken
MarktkapitalisatieUS$2.09b
Inkomsten(TTM)-US$83.50m
Inkomsten(TTM)US$267.23m

7.7x

P/S-verhouding

-24.7x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
WGS resultatenrekening (TTM)
InkomstenUS$267.23m
Kosten van inkomstenUS$104.59m
BrutowinstUS$162.63m
Overige uitgavenUS$246.13m
Inkomsten-US$83.50m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-3.04
Brutomarge60.86%
Nettowinstmarge-31.25%
Schuld/Eigen Vermogen Verhouding25.4%

Hoe presteerde WGS op de lange termijn?

Bekijk historische prestaties en vergelijking